海尔生物医学在其罗马首脑会议上推出了符合欧盟要求的新医疗装置,并扩大了欧洲实验室设备布局。 Haier Biomedical launched new EU-compliant medical devices and expanded its European lab equipment lineup at its Rome summit.

Haier Heaier生物医学在罗马举行了欧洲伙伴峰会, 来自23个国家的37个伙伴聚集一堂, 推进其“欧洲为欧洲”战略。 Haier Biomedical held its European Partner Summit in Rome, bringing together 37 partners from 23 countries to advance its "In Europe, for Europe" strategy. 该公司揭幕了经欧盟MDR认证的等离子体Apheresis系统XJ-III,并扩大了实验室设备组合,包括CO2孵化器、离心机、生物安全柜和冷藏,所有设备都强调能源效率和遵守规章。 The company unveiled the EU MDR-certified Plasma Apheresis System XJ-III and expanded its portfolio of lab equipment, including CO₂ incubators, centrifuges, biosafety cabinets, and cold storage, all emphasizing energy efficiency and regulatory compliance. 报告着重介绍了与U-Blood平台和RFID驱动的生物库系统在自动化和智能血液管理方面取得的进展,以改进可追踪性和减少废物。 It highlighted progress in automation and intelligent blood management with the U-Blood platform and RFID-enabled biobank systems to improve traceability and reduce waste. 欧洲仍然是一个关键的增长市场,2025年国际收入达到8.4亿元,占总收入的36%以上,由两位数增长驱动。 Europe remains a key growth market, with international revenue reaching RMB 840 million in 2025—over 36% of total revenue—driven by double-digit growth. 该公司的目标是到2027年实现50%以上的国际收入,到2028年实现50%以上的非制冷收入。 The company aims for over 50% international revenue by 2027 and over 50% non-refrigeration revenue by 2028.